Cargando…
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF). The mechanisms by which SGLT2 inhibitors reduce such risk are likely to be independent of diabet...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722318/ https://www.ncbi.nlm.nih.gov/pubmed/33287812 http://dx.doi.org/10.1186/s12933-020-01191-5 |